TG Therapeutics (NASDAQ:TGTX) Research Coverage Started at TD Cowen

TD Cowen initiated coverage on shares of TG Therapeutics (NASDAQ:TGTX) in a report issued on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $50.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts also recently commented on TGTX. The Goldman Sachs Group boosted their price target on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. B. Riley raised their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $49.00 price target on shares of TG Therapeutics in a report on Wednesday, September 18th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $34.43.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX opened at $25.06 on Tuesday. TG Therapeutics has a 12-month low of $7.17 and a 12-month high of $26.41. The company’s 50 day moving average price is $23.44 and its two-hundred day moving average price is $19.89. The firm has a market cap of $3.87 billion, a PE ratio of 108.96 and a beta of 2.21. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. The business had revenue of $73.47 million for the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The firm’s quarterly revenue was up 357.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.34) earnings per share. Equities research analysts predict that TG Therapeutics will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On TG Therapeutics

A number of hedge funds have recently made changes to their positions in TGTX. NBC Securities Inc. lifted its stake in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in shares of TG Therapeutics during the second quarter worth $35,000. Blue Trust Inc. increased its holdings in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 849 shares in the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter valued at $53,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in TG Therapeutics during the 1st quarter worth $58,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.